Molecular pathology of lung cancer: key to personalized medicine

Global cancer statistics

2011 • 55,498 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2010 • 5,268 citations

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

2007 • 5,137 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

2011 • 4,371 citations

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 • 4,320 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Cancer statistics, 2011

2011 • 4,080 citations

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

2009 • 3,957 citations

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

2011 • 3,882 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 • 3,476 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

2004 • 3,304 citations

ERBB receptors and cancer: the complexity of targeted inhibitors

2005 • 3,200 citations

Epidermal growth factor receptor mutations in lung cancer

2007 • 2,966 citations

Somatic mutations affect key pathways in lung adenocarcinoma

2008 • 2,653 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

2010 • 2,394 citations

Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma

1994 • 2,375 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Lung Cancer

2008 • 2,224 citations

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

2010 • 2,043 citations

EGFR Antagonists in Cancer Treatment

2008 • 1,940 citations

Epidermal growth factor receptor (EGFR) signaling in cancer

2005 • 1,852 citations

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 • 1,834 citations

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

2009 • 1,805 citations

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

2002 • 1,749 citations

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

2006 • 1,691 citations

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

2008 • 1,606 citations

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

2004 • 1,600 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

Epidermal growth factor receptor: mechanisms of activation and signalling

2003 • 1,514 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

2011 • 1,492 citations

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 • 1,467 citations

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

2003 • 1,445 citations

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

2005 • 1,418 citations

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 • 1,253 citations

Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 • 1,206 citations

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 • 1,196 citations

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 • 1,163 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 • 1,081 citations

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

2010 • 1,008 citations

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

2010 • 1,007 citations

High-throughput oncogene mutation profiling in human cancer

2007 • 995 citations

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

2001 • 988 citations

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 • 965 citations

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

2005 • 948 citations

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 • 941 citations

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

2009 • 899 citations

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

2011 • 877 citations

The anaplastic lymphoma kinase in the pathogenesis of cancer

2007 • 841 citations

New driver mutations in non-small-cell lung cancer

2012 • 829 citations

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 • 824 citations

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

2008 • 802 citations

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

1983 • 792 citations

EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment

2005 • 792 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 • 782 citations

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2009 • 765 citations

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 • 735 citations

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

2005 • 724 citations

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

2009 • 712 citations

Non–Small Cell Lung Cancer

2010 • 710 citations

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 704 citations

The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

2009 • 700 citations

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2008 • 688 citations

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

2005 • 669 citations

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

2011 • 668 citations

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

2000 • 667 citations

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

2009 • 665 citations

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

2005 • 640 citations

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

2005 • 636 citations

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

2010 • 630 citations

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

2005 • 609 citations

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

2010 • 593 citations

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

1990 • 593 citations

The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling

1997 • 591 citations

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

2011 • 587 citations

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

2011 • 563 citations

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

2011 • 542 citations

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary

2011 • 539 citations

The biology and treatment of EML4-ALK non-small cell lung cancer

2010 • 535 citations

Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

2009 • 532 citations

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

2009 • 519 citations

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

2009 • 519 citations

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

2005 • 508 citations

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

2006 • 507 citations

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

2011 • 489 citations

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

2009 • 481 citations

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

2008 • 480 citations

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2011 • 470 citations

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

2008 • 465 citations

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

2003 • 457 citations

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

2006 • 457 citations

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

2009 • 441 citations

Identification of Novel Isoforms of theEML4-ALKTransforming Gene in Non–Small Cell Lung Cancer

2008 • 428 citations

EGFR Signaling and Drug Discovery

2009 • 427 citations

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

2009 • 424 citations

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

2010 • 415 citations

Anaplastic lymphoma kinase: signalling in development and disease

2009 • 410 citations

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

2008 • 401 citations

Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

2006 • 398 citations

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

2002 • 396 citations

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

2009 • 381 citations

Update onEpidermal Growth Factor ReceptorMutations in Non–Small Cell Lung Cancer

2006 • 359 citations

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

2008 • 351 citations

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

1999 • 329 citations

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

2009 • 313 citations

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

2008 • 310 citations

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

2009 • 304 citations

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

2008 • 302 citations

Targeting Anaplastic Lymphoma Kinase in Lung Cancer

2011 • 297 citations

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

2010 • 292 citations

Raf kinases: Function, regulation and role in human cancer

2007 • 291 citations

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

2008 • 290 citations

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

2003 • 284 citations

ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer

2005 • 282 citations

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

2009 • 282 citations

Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy

2008 • 279 citations

PIK3CA mutation status in Japanese lung cancer patients

2006 • 273 citations

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

2010 • 270 citations

The Biology of Epidermal Growth Factor Receptor in Lung Cancer

2004 • 267 citations

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

2009 • 267 citations

The molecular pathology of cancer

2010 • 267 citations

Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

2004 • 259 citations

EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

2009 • 257 citations

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

2006 • 252 citations

Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

2007 • 250 citations

Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

2010 • 244 citations

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

2009 • 242 citations

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

2010 • 242 citations

The type III epidermal growth factor receptor mutation

2001 • 241 citations

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

2008 • 240 citations

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

2011 • 235 citations

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

2009 • 234 citations

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

2009 • 227 citations

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

2010 • 223 citations

Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

1994 • 220 citations

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

2011 • 219 citations

Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas

2006 • 213 citations

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

2010 • 213 citations

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR

2010 • 207 citations

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study

2011 • 207 citations

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

2008 • 204 citations

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

2011 • 204 citations

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

2010 • 202 citations

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

2011 • 201 citations

EGFR Mutations in Lung Adenocarcinomas

2008 • 201 citations

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

2008 • 194 citations

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

2009 • 192 citations

EGFR-mutated lung cancer: a paradigm of molecular oncology

2010 • 187 citations

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

1997 • 186 citations

Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR

2011 • 180 citations

Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells BearingEGFRGene Mutation and Amplification

2007 • 168 citations

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

2004 • 167 citations

Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor

1998 • 163 citations

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

2008 • 161 citations

KRAS and BRAF: drug targets and predictive biomarkers

2010 • 159 citations

Evidence for Common Clonal Origin of Multifocal Lung Cancers

2009 • 154 citations

Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

2010 • 150 citations

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations

2010 • 150 citations

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2009 • 148 citations

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

2011 • 146 citations

Detection ofEGFRMutations in Archived Cytologic Specimens of Non–Small Cell Lung Cancer Using High-Resolution Melting Analysis

2006 • 143 citations

Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers

1998 • 143 citations

Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

2006 • 142 citations

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2009 • 139 citations

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

2011 • 134 citations

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

2010 • 131 citations

Organization of the human hepatocyte growth factor-encoding gene

1991 • 131 citations

EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

2010 • 126 citations

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

2010 • 121 citations

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

2010 • 119 citations

Impact of EGFR mutation analysis in non-small cell lung cancer

2008 • 117 citations

Comparative Genomic Sequence Analysis and Isolation of Human and Mouse Alternative EGFR Transcripts Encoding Truncated Receptor Isoforms

2001 • 115 citations

Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib

2007 • 108 citations

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

2008 • 107 citations

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

2010 • 103 citations

Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR

2011 • 99 citations

Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites

2009 • 94 citations

Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway

2006 • 94 citations

The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma

2008 • 93 citations

Micropapillary Lung Adenocarcinoma

2009 • 92 citations

Adenosquamous Carcinoma of the Lung

2011 • 91 citations

MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy

2010 • 88 citations

Mechanisms of tumor resistance to EGFR-targeted therapies

2009 • 87 citations

Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma

2011 • 87 citations

Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process

2007 • 86 citations

EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC

2010 • 85 citations

Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer

2008 • 83 citations

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

2011 • 83 citations

Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

2007 • 82 citations

Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations

2010 • 79 citations

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

2007 • 77 citations

Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

2010 • 77 citations

Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas

2007 • 72 citations

Large-Cell Neuroendocrine Carcinoma of the Lung HarboringEGFRMutation and Responding to Gefitinib

2011 • 72 citations

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

2009 • 71 citations

Molecular Genetic Pathology

2008 • 68 citations

Discovery of selective irreversible inhibitors for EGFR-T790M

2010 • 67 citations

Monoclonal antibodies as effective therapeutic agents for solid tumors

2004 • 64 citations

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers

2011 • 62 citations

Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression

2006 • 61 citations

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

2010 • 56 citations

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas

2007 • 55 citations

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

2010 • 53 citations

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

2007 • 51 citations

Clinical Implications of MET Gene Copy Number in Lung Cancer

2010 • 49 citations

The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases

2012 • 48 citations

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

2011 • 48 citations

EGFRvIII mutation in lung cancer correlates with increased EGFR copy number

2007 • 47 citations

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

2009 • 43 citations

Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung

2005 • 38 citations

Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate

2006 • 36 citations

Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis

2008 • 35 citations

ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?

2010 • 31 citations

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies

2010 • 30 citations

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti‐EGFR‐based therapy?

2010 • 30 citations

Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer

2009 • 29 citations

Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K

2004 • 28 citations

A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non–Small-Cell Lung Cancer

2010 • 28 citations

Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma

2008 • 26 citations

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

2008 • 25 citations

Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy

2011 • 25 citations

Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization

2010 • 23 citations

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation

2008 • 19 citations

Recurrent EML4–ALK-associated lung adenocarcinoma with a slow clinical course

2010 • 16 citations

A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond

2010 • 14 citations

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

2011 • 10 citations

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy

2010 • 10 citations

Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

2011 • 6 citations

Correlation of genes associated with drug response to prognosis of large cell lung carcinoma

2011 • 5 citations